IRVINGTON, N.Y., Sept. 25, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, will be exhibiting MelaFind® at the German Skin Cancer Congress (ADO) that will take place in Essen, Germany on September 26-28, 2013. The DeCOG (Dermatologic Cooperative Oncology Group) is affiliated with the German Cancer Society (DKG) and the German Dermatologic Society (DDG).
Help employers find you! Check out all the jobs and post your resume.
